Hydroxyapatite porous scaffold engineered with biological polymer hybrid coating for antibiotic Vancomycin release.
The purpose of this study is to improve hydroxyapatite (HA) porous scaffolds via coating with biological polymer-HA hybrids for use as wound healing and tissue regeneration. Highly porous HA scaffolds, fabricated by a polyurethane foam reticulate method, were coated with hybrid coating solution, consisting of poly(epsilon-caprolactone) (PCL), HA powders, and the antibiotic Vancomycin. The PCL to HA ratio was fixed at 1.5 and the drug amounts were varied [drug/(PCL + HA) = 0.02 and 0.04]. For the purpose of comparison, bare HA scaffold without the hybrid coating layer was also loaded with Vancomycin via an immersion-adsorption method. The hybrid coating structure and morphology were observed with Fourier transformed infrared (FT-IR) spectroscopy and scanning electron microscopy (SEM). The effects of the hybrid coating on the compressive mechanical properties and the in vitro drug release of the scaffolds were investigated in comparison with bare HA scaffold. The PCL-HA hybrid coating altered the scaffold pore structure slightly, resulting in thicker stems and reduced porosity. With the hybrid coating, the HA scaffold responded to an applied compressive stress more effectively without showing a brittle failure. This was attributed to the shielding and covering of the framework surface by the coating layer. The encapsulated drugs within the coated scaffold was released in a highly sustained manner as compared to the rapid release of drugs directly adsorbed on the pure HA scaffold. These findings suggest that the coated HA scaffolds expand their applicability in hard tissue regeneration and wound healing substitutes delivering bioactive molecules.
Kim
Hae-Won
HW
School of Materials Science and Engineering, Seoul National University, Seoul 151-742, Korea. hwkim@snu.ac.kr
Knowles
Jonathan C
JC
Kim
Hyoun-Ee
HE
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry; D020099:Coated Materials, Biocompatible / Q000138:chemical synthesis / Q000737:chemistry*; D019245:Compressive Strength; D016503:Drug Delivery Systems; D017886:Durapatite / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D011091:Polyesters / Q000737:chemistry*; D016062:Porosity; D023822:Tissue Engineering; D014640:Vancomycin / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible; D011091:Polyesters; D014640:Vancomycin; D017886:Durapatite
Biomaterials. 2002 Aug;23(16):3449-54
12099288
Science. 1993 May 14;260(5110):920-6
8493529
Dent Mater. 1998 Mar;14(2):137-41
10023203
J Orthop Res. 2002 Mar;20(2):274-80
11918306
Dent Mater. 2003 Sep;19(6):478-86
12837395
J Mater Sci Mater Med. 2003 Oct;14(10):899-904
15348528
Biomaterials. 2003 Aug;24(19):3277-84
12763455
J Periodontol. 1998 May;69(5):507-20
9623893